1 Comment
Enantiomeric purity in chiral molecules – such as Transo-Pharm’ s Epinephrine Base and Bitartrate – have been in the focus of the health authorities for some time now. Transo-Pharm is well prepared to fully satisfy the more stringent requirements with their state-of-the-art stereo-selective manufacturing process. Transo-Pharm is therefore in the position to achieve an Enantiomeric Excess (ee) of 99% in commercial production for several years now. This is a significant contribution to ensure patient safety.
Please find the full article below. Learn more about the science behind this topic.
No Nitrosamine risk with Epinephrine Base / Bitartrate from Transo-Pharm as our recently conducted risk evaluation report reveals.
The conclusion is now available on request.
|
Categories
All
Archives
October 2024
|